| ★阿修羅♪ > 不安と不健康10 > 268.html ★阿修羅♪ |
|
| Tweet |
(回答先: ブラジル、エイズ薬を提供するアボットと交渉決裂、非ブランド薬生産へ[Independent、BBC] 投稿者 ネオファイト 日時 2005 年 7 月 08 日 17:03:56)
8日に交渉妥結し、ブラジル政府は向こう6年は特許を破らずにエイズ薬のより安価な提供を受けることになった。2億5千万ドル予算を削減できる。エイズ団体はブラジル政府が特許を認めたことに対して怒っている。
BBCは同じリンクで記事が変更されています。
http://news.bbc.co.uk/2/hi/americas/4662877.stm
Last Updated: Saturday, 9 July, 2005, 01:46 GMT 02:46 UK
Brazil reaches drug patent deal
Brazil has decided not to break the patent on a key HIV/Aids drug after its US manufacturer agreed to reduce the drug's price over the next six years.
The Brazilian government and America's Abbott Laboratories were on the brink of agreement yesterday over an anti-Aids drug which will probably see the pharmaceuticals company slash the price of the key medicine.
Reports in Brazil said Abbott had agreed to supply Kaletra for $0.68 a pill. Brazil currently pays $1.17 a pill. The company would not comment.
The move came as leaders at the G8 meeting in Gleneagles made fighting Aids part of their plan to help Africa, promising universal access to Aids treatments by 2010.
Several countries are fighting their own battles to bring down the cost of Aids drugs. Brazil, which says 600,000 of its people carry HIV, gave Abbott an ultimatum two weeks ago, saying unless the company cut the price of Kaletra it would ignore the patent and produce its own version at a fraction of the cost.
The deadline for Abbott to respond was Wednesday, but discussions have continued in the past few days.
The process has become confused because Humberto Costa, Brazil's health minister who threatened to ignore the Kaletra patent, was replaced this week by Saraiva Felipe. It is not clear whether Mr Felipe will follow Mr Costa's line.
The dispute between Brazil and Abbott could have implications for the global fight against HIV/ Aids and the biotech industry. If Brazil were to issue a compulsory licence on Kaletra, it would be the first time a country has invoked its rights under concessions won during World Trade Organisation negotiations that allow governments to make cheap copies of drugs to try to tackle local health emergencies.
Brazil is one of several countries which have threatened to use their WTO rights to issue compulsory licences. So far, each clash has ended in drugs companies agreeing to slash their prices.
The process was condemned this week by the international trade body which represents drugs companies. The Geneva-based International Federation of Pharmaceutical Manufacturers described Brazil's campaign as "theft".
Abbott said last week that the country's threat to introduce compulsory licensing was "a mis-step that puts short-term manoeuvring ahead of the access to new and improved treatments".
The charity ActionAid said Brazil was entitled to issue a compulsory licence against Abbott because Kaletra costs Brazil $107m (£62m) a year, one third of its budget for Aids drugs.
Almir Pereira, ActionAid's programme co-ordinator on Aids in Brazil, said: "We want the government to adopt a compulsory licence on this specific drug and to show more widely that the WTO trade negotiations at Doha said public interest must be taken into account in trade negotiations."
▲このページのＴＯＰへ HOME > 不安と不健康10掲示板
題名には必ず「阿修羅さんへ」と記述してください。